Emerging studies suggest this peptide, a dual agonist targeting both incretin and GIP , may provide a notable development for weight loss . Initial human trials have demonstrated substantial decreases in visceral fat , possibly surpassing existing weight-loss therapies . However , additional evaluation is needed to completely assess its lasting eff